Amgen (NASDAQ:AMGN) executives outlined the company’s oncology research and development priorities and provided updates on ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

When measured against the market's most prolific capital-return leaders, Amgen’s ability to maintain this level of ...

Amgen Inc. (NASDAQ:AMGN) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Amgen Inc. ...

Executives at Amgen (NASDAQ:AMGN) outlined several upcoming clinical milestones and recent data updates across its ...

But Amgen’s true success stems from putting people first. By creating an environment where innovation, inclusion and ...

On February 17, 2026, Amgen Inc. issued and sold a total of $4 billion in senior unsecured notes across four tranches maturing between 2031 and 2056, carrying coupons ranging from 4.200% to 5.650%.

Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 3:15 PM ESTCompany ParticipantsJean-Charles Soria - Senior Vice ...

Amgen led four borrowers that raised $6.4bn on Monday. It was joined by Howmet Aerospace (Baa1/A-), which came to the market ...

Piper Sandler Virtual Novel Targets in Immunology Symposium February 12, 2026 5:00 PM ESTCompany ParticipantsPaul Burton - Senior VP ...

The drug, MariTide, also helped patients with obesity and Type 2 diabetes lose up to 17% of their weight after a year. The company said it did not observe a plateau in either group of patients, which ...

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on new obesity drug data, and Merck laid out its post-Keytruda future.